> Wyeth Pharmaceuticals won a $32 million contract from the NIH to develop HIC drugs. Report
> China's Lijun International Pharmaceutical plans to raise $79 million in a Hong Kong IPO. Report
> FDA regulatory staffers are advising against the approval of an experimental ADHD patch from Noven Pharmaceuticals and Shire Pharmaceuticals. Article
> Lexicon Genetics has expanded its drug discovery alliance with Genentech. Release
> Shares of Germany's MediGene surged after it announced that the FDA has accepted its NDA for Polyphenon E ointment, an experimental treatment for genital warts. MediGene says that talks with a likely marketing partner for the US are already well underway and some analysts are expecting a new out-licensing deal for the therapy in coming days. Release
> Chutes & Ladders: OncoMed Pharmaceuticals of Mountain View, CA, has named Paul J. Hastings as its new president and CEO. Release
> KV Pharma has inked a licensing deal for Eastern Europe. Report
> As patents on blockbuster drugs expire, the big multinationals are scrambling to come up with a new approach to drug development. Report
> Doctors have been warned by the FDA against using Genzyme's Campath to treat multiple sclerosis. The drug--approved for leukemia--is currently in clinical trials for MS. Report
And Finally… Investigators have found widespread problems with the government's drug discount card program that was used in the lead-up to a new Medicare drug subsidy. Article